InterMune's (ITMN) Esbriet Survey Results Favorable - Goldman Sachs - StreetInsider.com

Goldman Sachs said results of a recent survey showed favorable results for InterMune's (NASDAQ: ITMN) Esbriet for IPF, which has an ongoing European launch. The survey showed solid prescribing base and increasing usage among high prescribers. Goldman ...

Canaccord Genuity Reiterates a 'Buy' on InterMune Inc. (ITMN); Reducing Estimates and PT - StreetInsider.com

Analyst, Ritu Baral, said, "Reiterate rating, lowering target to $15 on lower, but still blockbuster, Esbriet (pirfenidone) sales prospects. Esbriet is ITMN’s drug for idiopathic pulmonary fibrosis (IPF), an orphan lung disease. We see good Esbriet EU ...

InterMune to Sell Actimmune Rights - Yahoo Finance

Actimmune sales for the year 2011 were $20.2 million. Notably, the company stopped its efforts for additional indications for Actimmune, as it turned its focus on its lead product Esbriet. Management conceded that Actimmune has so far been the ...

InterMune agrees to sell immune drug Actimmune - Yahoo Finance

InterMune said the deal will give it additional cash and financial flexibility as it focuses its business around its lung disease drug Esbriet and studies new drug candidates. The company said it stopped studying new uses for Actimmune several ...

InterMune Sells Actimmune to Vidara for $55M - Genetic Engineering News

“The divesture of Actimmune will provide additional capital for InterMune to continue to focus on and invest in the registration and commercialization of Esbriet® in Europe and elsewhere and to continue to advance our R&D program," comments ...

Stocks to watch Tuesday: Nordson, Georgia Gulf - Marketwatch

Proceeds will be used by InterMune to further plans for the commercialization of pulmonary fibrosis drug Esbriet in Europe and elsewhere and for research and development. The Actimmune transaction’s expected to close during the second quarter.

InterMune to Divest Actimmune® (Interferon Gamma-1b) - Seekingalpha.com

The divesture of Actimmune will provide additional capital for InterMune to continue to focus on and invest in the registration and commercialization of Esbriet® (pirfenidone) in Europe and elsewhere and to continue to advance our R&D programs.

UPDATE: Morgan Stanley Lowers InterMune's PT - Benzinga

In the report, Morgan Stanley said, "Esbriet revenue fell short of expectations, likely driven by a) sequentially lower new pt adds and b) a possibly higher than expected drop-out rate (we model 20% annually). While we expect new pt adds to vary somewhat Q ...

InterMune deal delivers $55M in fresh fuel for fibrosis drug - FierceBiotech

The money is being used to fuel the launch of pirfenidone (Esbriet) in Europe, a new treatment for idiopathic pulmonary fibrosis. The FDA, though, rejected the drug in 2010, forcing InterMune to mount a new late-stage study as the company ...

Rare and Niche Diseases Catalyst Monitor - Key Event Analysis H1 2012 - SBWire

Intermune’s Esbriet (pirfenidone), for idiopathic pulmonary fibrosis (IPF): additional launches in France, Spain, and Italy in H1. Reasons to Buy - Understand the key therapeutic areas that are driving the rare and niche disease markets, which will ...